Jeff Bezos Is Funding a Wild Hunt for the Brain’s ‘Core Algorithm’

The buried tension here is that Flourish is not just betting on a different research direction, it is implicitly betting that the current scaling consensus is wrong, or at least incomplete. That is a much more aggressive claim than the funding headline suggests.

The timing is striking when set against the infrastructure spending wave we have been tracking. Alphabet's $80 billion capital raise (covered June 1) and SoftBank's $87.3 billion French infrastructure commitment both reflect a conviction that compute scale is the primary competitive lever. Flourish's thesis runs in the opposite direction: that architectural insight, not raw capital, is the binding constraint. Richard Sutton's argument from The Decoder (June 1), that generative AI lacks the evaluation loops needed for genuine discovery, provides an intellectual frame that actually supports what Flourish is attempting. The two pieces of coverage, read together, suggest a real fault line forming between the scale-first camp and a smaller but well-capitalized group betting on biological principles as a shortcut past the compute wall.

Watch whether Flourish publishes peer-reviewed results within 18 months that demonstrate a measurable capability advantage on a standard benchmark using fewer parameters. If they do not, the $2.5B valuation will be very difficult to defend against labs that can simply outspend them.